Latest News and Press Releases

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial...

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The...

ZUG, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment ...

ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company, the annual equity incentive...

ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on...

ZUG, Sviss, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) („Oculis” eða „félagið”), tilkynnti í dag niðurstöður aðalfundar 2025, sem haldinn var 13. maí 2026 í...

ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on...

Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026Licaminlimab PREDICT-1 Trial in Active Site...

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June...

ZUG, Sviss, May 11, 2026 (GLOBE NEWSWIRE) -- Þróun miðar samkvæmt áætlun með OCS-01 í fararbroddi þar sem mikilvægum áfanga var náð (lok síðustu eftirfylgniheimsóknar) í báðum fasa 3...